Target Antigen Selection for ADCs

Introduction

This naturally leads to a crucial question: What makes a protein a good target for an ADC? Not all cell surface proteins are created equal in this regard. The success of an ADC is fundamentally dependent on the biological characteristics of the antigen it is designed to attack.

Today's lesson directly addresses this by focusing on our next learning outcome: Analyze the key biological characteristics of an ideal target antigen for an ADC, including expression levels, heterogeneity, and internalization rate.

We will dissect the criteria that drug developers use to select ADC targets. For your work in market access, understanding these criteria is essential. It allows you to critically evaluate the potential of a new ADC, understand its likely safety and efficacy profile, and articulate its strategic position within the competitive landscape.

By the end of this lesson, you will have a framework for assessing the quality of an ADC target, which is the first and most critical step in designing a successful "guided missile" therapy.

1. The Cornerstone of ADC Targeting: Specificity

Before we dive into the detailed criteria, let's establish the single most important principle of ADC target selection: tumor selectivity. The entire premise of an ADC is to deliver a highly toxic payload specifically to cancer cells while sparing healthy ones. This is only possible if the target antigen is much more abundant on tumor cells than on normal tissues.

To hear this emphasized, let's watch a very brief clip from a talk by an expert in the field.

This principle of differential expression creates the therapeutic window—the dose range where the ADC is effective against the tumor but tolerated by the patient. If a target is also highly expressed on vital healthy tissues, the ADC is likely to cause severe "on-target, off-tumor" toxicity, limiting its clinical utility.

2. The Anatomy of an Ideal Target

With tumor selectivity as our foundation, we can now build a more detailed profile of an ideal target antigen. Several biological features are considered. The two resources below provide excellent and complementary overviews of these characteristics.

Based on these readings, let's synthesize the four key characteristics of an ideal ADC target.

Characteristic 1: High Antigen Density

• What it is: The target should be present in large numbers on the surface of each cancer cell. The article "Design Criteria For ADC Drugs" mentions a target of over 100,000 (10⁵) receptors per cell for highly expressed antigens like HER2.
• Why it matters: A higher antigen density allows more ADC molecules to bind to and be internalized by each cancer cell. As the review from Vaccines notes, there is an almost linear relationship between surface antigen density and the intracellular concentration of the ADC. More payload per cell generally translates to a more potent cytotoxic effect.

Characteristic 2: Homogeneous Expression

• What it is: Ideally, the target antigen should be expressed uniformly across all cancer cells within a tumor.
• Why it matters: Tumors are often heterogeneous, meaning some subclones of cells may express the target at high levels, while others express it at low levels or not at all. If an ADC relies solely on direct targeting, these antigen-low/negative cells will survive and can lead to disease relapse.
• The Solution (A Recap): As we discussed in the previous lesson, this is where the bystander effect becomes critical. An ADC with a membrane-permeable payload can kill the initial target cell and then diffuse out to kill neighboring antigen-negative cells, overcoming the challenge of tumor heterogeneity.

Characteristic 3: Efficient Internalization

• What it is: After the ADC binds to the antigen, the ADC-antigen complex must be rapidly pulled inside the cell via endocytosis.
• Why it matters: As we saw in the mechanism of action, most ADCs require delivery to the lysosome for the payload to be released. If the target antigen is not internalized, or is internalized very slowly, the payload cannot be effectively liberated inside the cell, rendering the ADC ineffective.

Characteristic 4: High Stability (Minimal Shedding)

• What it is: The target antigen should be a stable, integral part of the cell membrane and not be "shed" or released into the bloodstream. Some membrane proteins have their extracellular domains (ectodomains) cleaved by enzymes.
• Why it matters: Shed antigens circulating in the blood act as decoys. They create a "sink" by binding to the ADC before it can ever reach the tumor. This reduces the amount of active drug that reaches its intended target and can lead to the need for higher, potentially more toxic, doses.

3. The Real World: Trade-offs and Nuances

In practice, it is exceptionally rare to find a target that is perfect across all four criteria. ADC development is therefore an exercise in balancing these properties and making intelligent design trade-offs. Your biochemistry background gives you a great foundation for appreciating these complexities.

• Internalization vs. Bystander Effect: If an ADC is designed with a highly potent, membrane-permeable payload and a cleavable linker (enabling a strong bystander effect), the requirement for rapid internalization can be relaxed. The payload can be released extracellularly near the tumor and still diffuse into cells.
• The Binding-Site Barrier (BSB): This is a phenomenon where an ADC with very high affinity for a densely expressed target binds so effectively to the first layer of tumor cells it encounters (e.g., around a blood vessel) that it fails to penetrate deeper into the tumor mass. Counter-intuitively, as mentioned in the Vaccines article, a small amount of antigen shedding might help mitigate BSB by "pre-occupying" some ADC molecules, allowing others to travel further into the tumor before binding.

This highlights that the "ideal" characteristics are not absolute rules but guiding principles that must be considered in the context of the other two ADC components: the linker and the payload.

Self-Assessment

Let's apply these concepts. Consider the following scenarios:

1. You are evaluating a potential ADC target for a solid tumor. Preclinical data shows it is highly and specifically expressed on the tumor and internalizes rapidly. However, the expression is known to be very heterogeneous. What property would you want to ensure the ADC has to maximize its chances of success?
2. A different target is being considered. It has moderate but very homogeneous expression and is not shed. However, it is known to internalize slowly. What kind of linker and payload combination might be best suited to overcome this limitation?
3. Why is a target like HER2, which is also expressed at low levels on some normal cells (e.g., in the heart and GI tract), a viable ADC target, leading to highly successful drugs like Kadcyla and Enhertu?

Conclusion

In this lesson, we moved from the "how" of the ADC mechanism to the "where," analyzing the essential features of the target antigen that enable the entire process.

Key Takeaways:

• The most critical characteristic of an ADC target is tumor selectivity: high expression on cancer cells and low-to-no expression on healthy tissues. This establishes the therapeutic window.
• The ideal target profile also includes high antigen density, homogeneous expression, efficient internalization, and minimal shedding.
• In reality, perfect targets are rare. Successful ADC design involves a sophisticated process of balancing trade-offs, where the properties of the linker and payload are chosen to compensate for the imperfections of the target antigen.

Preview of the Next Lesson:

We've repeatedly touched on how the linker and payload can influence an ADC's function. In our next lesson, we will dive deep into this topic: Explain how linker chemistry (cleavable vs. non-cleavable) influences an ADC's efficacy, safety, and potential for a 'bystander effect'. This will complete our analysis of the core ADC components.